Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Farhan Taghizadeh

Otolaryngology Phoenix, AZ Medical Doctor

NPI 1114948353 CMS profile 765352

4602 N 16Th St, Fl 3, Phoenix, AZ 85016

Open in the dashboard

General payments

$45,854

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$17,710 paid to institutions, not to them · program year 2025

Through program year 2025, Farhan Taghizadeh of Phoenix, AZ is reported in the CMS Open Payments database as having received $45,854 across 213 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $17,710 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,379 25
2024 General $9,209 29
2023 General $7,790 30
2022 General $953 27
2021 General $594 29
2020 General $15,169 28
2019 General $9,759 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farhan Taghizadeh
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Farhan Taghizadeh were reported at $2,379. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Farhan Taghizadeh Otolaryngology median Middle half National median
2019 $9,759 $194 $82–$512 $163
2020 $15,169 $118 $42–$280 $114
2021 $594 $167 $63–$444 $132
2022 $953 $216 $84–$545 $149
2023 $7,790 $235 $93–$588 $160
2024 $9,209 $280 $111–$699 $164
2025 $2,379 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerin Medical Inc. $18,591 81 payments
  2. Allergan Inc. $14,437 5 payments
  3. Merz North America, Inc. $8,763 21 payments
  4. Stryker Corporation $951 15 payments
  5. Medtronic USA, Inc. $935 14 payments
  6. Medtronic, Inc. $602 7 payments
  7. Galderma Laboratories, L.P. $443 13 payments
  8. OptiNose US, Inc. $393 29 payments
  9. Musculoskeletal Transplant Foundation Inc. $151 3 payments
  10. Pulse Biosciences, Inc. $146 1 payment
  11. Other $442 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $14,372 1 payment
  2. Consulting Fee $12,400 16 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,150 2 payments
  4. Food and Beverage $6,704 180 payments
  5. Travel and Lodging $4,211 13 payments
  6. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. VIVAER STYLUS $18,219 65 payments
  2. ALLODERM $14,372 1 payment
  3. Xeomin $8,637 20 payments
  4. RHINAER STYLUS $1,709 34 payments
  5. NUVENT Sinus Surgery $872 13 payments
  6. Xhance $393 29 payments
  7. NUVENT Sinus Surgery $297 3 payments
  8. AUDION ET DILATION SYSTEM $219 3 payments
  9. XPRESS ENT DILATION SYSTEM $208 3 payments
  10. Vivaer RF Stylus $199 7 payments
  11. Other $1,986 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

312

Median for Otolaryngology: 297

Drug cost

$2,727

Median for Otolaryngology: $6,314

Branded share of claims

21.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 67 $1,497
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 68 $497
Amoxicillin Generic 67 $203
Mupirocin Generic 23 $123
Ciprofloxacin Hcl Generic 21 $115
Omeprazole Generic 16 $100
Cephalexin Generic 21 $97
Clindamycin Hcl Generic 18 $75
Acyclovir Generic 11 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$101,774

Medicare's payments for the services billed

Medicare patients

290

Average age 76

Services billed

841

155 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 53%
Ischemic heart disease 31%
Chronic kidney disease 28%
Diabetes 22%
Osteoporosis 22%
Depression 20%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record